Profile data is unavailable for this security.
About the company
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
- Revenue in USD (TTM)140.62m
- Net income in USD-85.66m
- Incorporated1997
- Employees593.00
- LocationGyre Therapeutics Inc12770 High Bluff Drive, Suite 150SAN DIEGO 92130United StatesUSA
- Phone+1 (619) 949-3681
- Fax+1 (302) 636-5454
- Websitehttps://www.gyretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics Inc | 37.23m | -111.65m | 914.60m | 140.00 | -- | 3.45 | -- | 24.57 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 932.52m | 85.00 | -- | 1.64 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| MiMedx Group Inc | 334.51m | 71.52m | 1.00bn | 895.00 | 18.02 | 6.43 | 12.58 | 3.00 | 0.3767 | 0.3393 | 2.15 | 1.06 | 1.72 | 2.82 | 6.58 | 373,754.20 | 41.80 | -4.14 | 53.13 | -5.90 | 83.50 | 83.61 | 24.36 | -2.70 | 2.71 | 9.00 | 0.111 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.00bn | 284.00 | -- | -- | -- | 24.14 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.03bn | 267.00 | -- | -- | -- | 2.49 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.05bn | 46.00 | -- | 3.30 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 1.06bn | 593.00 | -- | 18.75 | -- | 7.56 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.09bn | 173.00 | -- | 2.17 | -- | 12.21 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.09bn | 171.00 | -- | 1.80 | -- | 53.47 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.12bn | 280.00 | -- | 1.83 | -- | 6.93 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Sana Biotechnology Inc | 0.00 | -308.61m | 1.13bn | 328.00 | -- | 3.00 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 1.15bn | 284.00 | -- | 5.67 | -- | 14.27 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.16bn | 587.00 | -- | 0.7489 | -- | 14.58 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.20bn | 174.00 | -- | 4.04 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Data as of Jul 08 2024. Currency figures normalised to Gyre Therapeutics Inc's reporting currency: US Dollar USD
0.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 189.76k | 0.22% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 171.30k | 0.20% |
| Geode Capital Management LLCas of 31 Mar 2024 | 160.59k | 0.19% |
| Millennium Management LLCas of 31 Mar 2024 | 60.32k | 0.07% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 46.09k | 0.05% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 40.54k | 0.05% |
| Jane Street Capital LLCas of 31 Mar 2024 | 30.56k | 0.04% |
| Marshall Wace LLPas of 31 Mar 2024 | 25.54k | 0.03% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 24.07k | 0.03% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 20.03k | 0.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
